tbuckley/cabot-search huggingface dataset:
Chronic Auricular Fibrillation Without Organic Heart Disease
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Human Melanoma Gene Mapped by NIEHS/University of Utah
Journal: Environmental Health Perspectives (1993)

The simultaneous study of environmental and genetic factors has become practical with recent advances in techniques for measuring mutations or polymorphisms in DNA.One of the most important public health applications of molecular genetics, and of the Human Gen- ome Project, is the Dr. Jack A. Taylor description of genes that may affect suscep- tibility to disease.NIEHS is using basic genetic research to improve the ability to detect environmental toxins.NIEHS is collaborating with the Environmental Protection Agency and the National Center for Health Statistics to identify and test candidate susceptibility genes.Epidemiologic case-control studies allow the simultaneous examination of polymorphic genes, environmental expo- sures, and gene-gene and gene-environment interactions.Jack A. Taylor and Allen J. Wilcox of the NIEHS Epidemiology Branch are working with the EPA and NCHS to assemble a bank of DNA specimens with linked environmental exposure and health outcomes from 11,000 persons who repre- sent a random sample of the U.S. population.Subsamples from this collection will be used to establish precise gene frequencies for the entire U.S. population, as well as for ethnic and regional subpopulations.This information will be crucial for risk assessment and genetic screening.Taylor and Douglas A. Bell of the NIEHS Laboratory of Biochemical Risk Analysis are developing both laboratory techniques and methods for large-scale population studies of susceptibility.The strategy of identifying susceptibility genes and then testing them in epidemiologic studies will produce powerful tools for detecting environmental hazards.On a broader scale, this program will help lay the groundwork for a new era of health research that more fully integrates genetic and environmental factors as causes of human disease.
Twentieth National Meeting of the Reticuloendothelial Society
Journal: JNCI Journal of the National Cancer Institute (1983)

Twentieth National Meeting of the Reticuloendothelial Society Get access JNCI: Journal of the National Cancer Institute, Volume 70, Issue 6, June 1983, Page 1171, https://doi.org/10.1093/jnci/70.6.1171-b Published: 01 June 1983
Surgical Emergencies.
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Encephalitis Associated With Cat Scratch Disease—Broward and Palm Beach Counties, Florida, 1994
Journal: JAMA (1995)

On August 14, 1994, the Broward County Public Health Unit of the Florida Department of Health and Rehabilitative Services was notified of three children from Pompano Beach who were hospitalized with encephalitis attributed to cat scratch disease (CSD). All three children (aged 5, 6, and 11 years) were previously healthy and had no histories of seizure disorders or diagnoses of CSD. This report summarizes the investigation of these cases.
Acquired Immunodeficiency Syndrome Associated With Intravenous-Drug Use — United States, 1988
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Seropositive
Authors: Lala Tanmoy Das
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hepatology
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Angiotensin-Converting Enzyme: I. New Strategies for Assay
Authors: James W. Ryan, Alfred Chung, Una S. Ryan
Journal: Environmental Health Perspectives (1980)

The disposition of converting enzyme (kininase II) on the luminal surface of pulmonary endothelial cells is well established. Further, it is known that there is a net conversion of angiotensin I into angiotensin II as blood passes through the lungs. However, little is known about modulations of converting enzyme activity that may arise through, e.g., changes in the quality of inhalants, blood flow, or blood oxygenation. There are few data on the effects of lung disease. A major barrier to studies to examine for pathophysiologic modulations of converting enzyme is that of assay. The enzyme can be measured in terms of the rate of formation of angiotensin II from a known quantity of angiotensin I. However, both peptides are biologically active, and lungs contain other enzymes capable of degrading them. We have developed a series of radiolabeled, acylated tripeptides to improve our ability to examine for changes in the net converting enzyme of intact lungs. The enzyme, a dipeptidyl carboxypeptidase, is capable of removing C-terminal dipeptides from a variety of oligopeptides. We have prepared benzoyl-Gly-Gly-Gly (I), benzoyl-Pro-Phe-Arg (II), benzoyl-Gly-His-Leu (III), benzoyl-Phe-Ala-Pro (IV), and benzoyl-Phe-His-Leu (V), each containing a 3H-atom in the para position of the benzoyl moiety. Substrates I and III have been used previously in photometric assays of low sensitivity. II is the acylated C-terminal tripeptide of bradykinin, IV is an acylated tripeptide analog of BPP5a (&lt;Glu-Lys-Trp-Ala-Pro) and V is the acylated C-terminal tripeptide of angiotensin I. These substrates can be used in vitro or in vivo to measure converting enzyme. The 3H-labeled product is separable by partitioning between an organic solvent and acidified aqueous solution. The product is quantified by scintillation counting of the organic phase. The choice of substrate depends on the goals of the experiment: substrate I or III when wide variations in substrate concentrations are needed but high sensitivity is not; substrate IV when high sensitivity is needed.
Abstract 904: Hypoxic attenuation of ΔB-Raf-induced senescence
Authors: Soojeong Chang, Hyunsung Park
Journal: Cancer Research (2019)

Abstract Oncogene-induced senescence (OIS) is natural surveillance mechanisms against tumorigenesis. The in-vivo oxygen concentration around tumor microenvironment has been estimated as 3%~0.5%. We investigate the effects of physiological hypoxia (1.5% O2) and pathological hypoxia (&amp;lt;0.5% O2) on OIS. Expression of active ΔB-Raf in human lung fibroblast IMR90 cells triggered senescence processes such as activation of senescence associated-β-galactosidase (SA-β-gal) and senescence associated heterochromatin foci (SAHF). We found that hypoxic condition delayed onset of activation of SA-β-gal. Furthermore hypoxic condition blocked formation of heterochromatin foci which was identified as a hallmark of OIS with increase of histone methylation. Rearrangement of chromatin organization by activated ΔB-Raf was also inhibited under hypoxic condition. This study shows that tumor hypoxia assists the transformed cells to overcome an obstacle of senescence caused by oncogenes. [This study was supported by the National Research Foundation of Korea (NRF), grant 2016R1A2B4012840 and 2018R1A4A1025985] Citation Format: Soojeong Chang, Hyunsung Park. Hypoxic attenuation of ΔB-Raf-induced senescence [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 904.
Abstract 4291: p85α alters Gab2 phosphorylation profile in ovarian cancer
Authors: Xinran Li, Victor CY Mak, Annie NY Cheung, Gordon B. Mills, Lydia WT Cheung
Journal: Cancer Research (2019)

Abstract Dysregulation of phosphatidylinositol 3-kinase (PI3K), which is essential for various cellular processes, is a common event in cancers. PIK3R1 encodes the PI3K class IA regulatory subunit p85α, which binds the p110 catalytic subunit forming heterodimeric PI3K complex. The PI3K associates with receptor tyrosine kinase, for example through the docking protein Gab2, to initiate downstream signaling events. Downregulation of p85α is frequently seen in cancers. However, the signaling changes driven by the downregulation remain to be elucidated. Our data herein indicate that reduced p85α expression leads to changes in the phosphorylation status of Gab2 at multiple amino acid residues. PIK3R1 siRNA decreased the levels of phosphorylated Y452 (a site implicated in binding p85α) and S210 (a site that may mediate negative feedback of Gab2 activity). Meanwhile, we observed an increase in phosphorylated S623, which was shown to involve in STAT activation. These findings provide mechanistic insights on the pathway activation upon downregulation of p85α in cancer. Citation Format: Xinran Li, Victor CY Mak, Annie NY Cheung, Gordon B. Mills, Lydia WT Cheung. p85α alters Gab2 phosphorylation profile in ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4291.
Proctology
Authors: E. Parker Hayden
Journal: New England Journal of Medicine (1954)

IN attempting to select articles from recent surgical publications for inclusion in a progress report on proctology one is immediately confronted with the necessity of deciding what areas this term properly includes and what subjects are of greatest importance and interest. There are specialists in proctology who confine their work to diagnostic procedures and minor surgery of the anal canal and rectum only. Others, with training and the desire to do major surgery of the colon and rectum, include this wider field in the scope of their activity. Then there is the large group of general surgeons who do a . . .
School-based screening for tuberculous infection. A cost-benefit analysis
Authors: J. C. Mohle-Boetani
Journal: JAMA (1995)

<h3>Objective.</h3> —To compare tuberculin screening of all kindergartners and high school entrants (screen-all strategy) vs screening limited to high-risk children (targeted screening). <h3>Design.</h3> —Decision, cost-effectiveness, and cost-benefit analyses. <h3>Setting and Subjects.</h3> —Students in a large urban and rural county. <h3>Definitions.</h3> —High risk of tuberculous infection was defined as birth in a country with a high prevalence of tuberculosis. Low risk was defined as birth in the United States. <h3>Outcome Measures.</h3> —Tuberculosis cases prevented per 10000 children screened. Net costs, net cost per case prevented, benefit-cost ratio, and incremental cost-effectiveness. <h3>Results.</h3> —The screen-all strategy would prevent 14.9 cases per 10 000 children screened; targeted screening would prevent 84.9 cases per 10000 children screened. The screen-all strategy is more costly than no screening; the benefit-cost ratio is 0.58. Targeted screening would result in a net savings; the benefit-cost ratio is 1.2. Screening all children is cost saving only if the reactor rate is 20% or greater. The cost per additional case prevented for screening all children compared with targeted screening ($34 666) is more than twice as high as treatment and contact tracing for a case of tuberculosis ($16392). <h3>Conclusions.</h3> —Targeted screening of schoolchildren is much less costly than mass screening and is more efficient in prevention of tuberculosis. (<i>JAMA</i>. 1995;274:613-619)
THE MEDICAL STAFF AND THE HOSPITAL.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Drug combinations. A critique of proposed new federal regulations
Authors: F. G. McMahon
Journal: JAMA (1971)

The<i>Federal Register</i>of Feb 18, 1971, contained the new Food and Drug Administration (FDA) policy statement on fixed drug combinations. Physicians were solicited for comments within 30 days. The principal effect of the proposed new regulations is to threaten removal from the market of hundreds of prescription drug combinations and most of the socalled over-the-counter (OTC) drugs, ie, nonprescription drugs. Unless each active ingredient can be shown to<i>enhance drug efficacy</i>or<i>diminish side effects</i>, the combination will be removed. Whether one agrees with the proposed regulations or not, the removal of these drugs will have a profound effect on American medicine as now practiced. There are some obviously irrational combination drugs still on the market, such as Ritonic (containing androgen, estrogen, vitamins, minerals, and methylphenidate hydrochloride), which simply represent bad medicine. The avaricious marketing of such nostrums in the 1960's has helped create the present problem for the
PHYSICIANS AS POLITICIANS.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Request for Proposal(RFP)
Journal: JNCI Journal of the National Cancer Institute (1993)

Request for Proposal(RFP) Get access JNCI: Journal of the National Cancer Institute, Volume 85, Issue 11, 2 June 1993, Page 927, https://doi.org/10.1093/jnci/85.11.927-a Published: 02 June 1993
Positive Selection of Thymocytes
Authors: S. C Jameson
Journal: Annual Review of Immunology (1995)

Differentiation of αβ T cell receptor (TCR)-expressing T cells involves an obligatory interaction with self-major histocompatibility complex (MHC) molecules in the thymus. This process, called positive selection, both rescues thymocytes from programmed cell death and induces their differentiation into mature T cells. Another critical event in thymic development is to prevent maturation of hazardous autoreactive T cells; thus, mechanisms exist to eliminate T cells with self-reactive receptors (negative selection). How can these two pathways be distinguished? This question, which has long taxed immunologists, is more opposite because many features of the interactions in positive and negative selection are shared: Both processes are exquisitely MHC-allele specific, they involve MHC-bound peptide recognition, and employ at least some overlapping signal transduction pathways. However, resolution of this paradox has become much more feasible with the advent of powerful systems for withdrawing and reconstituting individual components involved in positive selection. This review describes recent advances in our understanding of the cells, receptors, ligands, and signaling pathways involved in this process. A pivotal part of this puzzle is the basis for discrimination between TCR ligands that induce positive vs negative selection. Recent work suggests that the peptide/MHC ligand for positive selection may bind with low avidity to the TCR. The implications of these data for the nature of T cell recognition during positive selection are discussed below.